Clarity reports mCRPC patient reaches undetectable PSA and negative PSMA PET in SECuRE trial

Reuters

Feb 23

Clarity reports mCRPC patient reaches undetectable PSA and negative PSMA PET in SECuRE trial

Clarity Pharmaceuticals reported an update from the Phase II cohort expansion of its SECuRE trial (NCT04868604) evaluating 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer. The company said another participant receiving 8 GBq per cycle achieved undetectable PSA after the first cycle and had a negative PSMA PET scan after the second cycle; related adverse events were Grade 1 and no hematological or renal adverse events were observed to date. Clarity stated this is the fifth patient with undetectable disease by radiographic assessment following 67Cu-SAR-bisPSMA treatment, and also provided follow-up that a previously reported participant remains undetectable on PSMA PET one month after a fourth cycle. The results were presented in this announcement, and the SECuRE trial is continuing enrollment with planned recruitment completion in 2026 while Phase III planning is ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN92976) on February 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2613787730"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613787730\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613787730?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-23 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613787730","market":"nz","top_or_hot":-1,"title":"Clarity reports mCRPC patient reaches undetectable PSA and negative PSMA PET in SECuRE trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clarity reports mCRPC patient reaches undetectable PSA and negative PSMA PET in SECuRE trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> reported an update from the Phase II cohort expansion of its SECuRE trial (NCT04868604) evaluating 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer. The company said another participant receiving 8 GBq per cycle achieved undetectable PSA after the first cycle and had a negative PSMA PET scan after the second cycle; related adverse events were Grade 1 and no hematological or renal adverse events were observed to date. Clarity stated this is the fifth patient with undetectable disease by radiographic assessment following 67Cu-SAR-bisPSMA treatment, and also provided follow-up that a previously reported participant remains undetectable on PSMA PET one month after a fourth cycle. The results were presented in this announcement, and the SECuRE trial is continuing enrollment with planned recruitment completion in 2026 while Phase III planning is ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CLRPF\">Clarity Pharmaceuticals Ltd.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN92976) on February 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clarity reports mCRPC patient reaches undetectable PSA and negative PSMA PET in SECuRE trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClarity reports mCRPC patient reaches undetectable PSA and negative PSMA PET in SECuRE trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-23 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clarity reports mCRPC patient reaches undetectable PSA and negative PSMA PET in SECuRE trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> reported an update from the Phase II cohort expansion of its SECuRE trial (NCT04868604) evaluating 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer. The company said another participant receiving 8 GBq per cycle achieved undetectable PSA after the first cycle and had a negative PSMA PET scan after the second cycle; related adverse events were Grade 1 and no hematological or renal adverse events were observed to date. Clarity stated this is the fifth patient with undetectable disease by radiographic assessment following 67Cu-SAR-bisPSMA treatment, and also provided follow-up that a previously reported participant remains undetectable on PSMA PET one month after a fourth cycle. The results were presented in this announcement, and the SECuRE trial is continuing enrollment with planned recruitment completion in 2026 while Phase III planning is ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CLRPF\">Clarity Pharmaceuticals Ltd.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN92976) on February 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL50jZBy:1","article_id":"2613787730","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613787730","pubTimestamp":1771855322,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clarity Pharmaceuticals reported an update from the Phase II cohort expansion of its SECuRE trial  evaluating 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer. The company said another participant receiving 8 GBq per cycle achieved undetectable PSA after the first cycle and had a negative PSMA PET scan after the second cycle; related adverse events were Grade 1 and no hematological or renal adverse events were observed to date. Clarity stated this is the fifth patient with undetectable disease by radiographic assessment following 67Cu-SAR-bisPSMA treatment, and also provided follow-up that a previously reported participant remains undetectable on PSMA PET one month after a fourth cycle. The results were presented in this announcement, and the SECuRE trial is continuing enrollment with planned recruitment completion in 2026 while Phase III planning is ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Whil","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","CU6.AU":"CLARITY PHARMACEUTICALS LTD"},"translate_title":"Clarity报告mCRPC患者在SECuRE试验中PSA检测不到，PSMA PET阴性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CU6.AU":0.9},"content_text":"Clarity reports mCRPC patient reaches undetectable PSA and negative PSMA PET in SECuRE trial\n    \n\nClarity Pharmaceuticals reported an update from the Phase II cohort expansion of its SECuRE trial (NCT04868604) evaluating 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer. The company said another participant receiving 8 GBq per cycle achieved undetectable PSA after the first cycle and had a negative PSMA PET scan after the second cycle; related adverse events were Grade 1 and no hematological or renal adverse events were observed to date. Clarity stated this is the fifth patient with undetectable disease by radiographic assessment following 67Cu-SAR-bisPSMA treatment, and also provided follow-up that a previously reported participant remains undetectable on PSMA PET one month after a fourth cycle. The results were presented in this announcement, and the SECuRE trial is continuing enrollment with planned recruitment completion in 2026 while Phase III planning is ongoing.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN92976) on February 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}